Breast cancer is one of the most frequent and aggressive primary tumors among women of all races. Matrix metalloproteinase (MMPs), a family of zinc-and calcium-dependent secreted or membrane anchored endopeptidases, is overexpressed in varieties of diseases including breast cancer. Therefore, noninvasive visualization and quantification of MMP in vivo are of great interest in basic research and clinical application for breast cancer early diagnosis. Herein, we developed a 
Introduction
Breast cancer is one of the leading causes of cancer death among women of all races. The life time risky for individuals to suffer breast cancer could be as high as 13% [1, 2] . Accurate diagnosis of breast cancer is very important and desirable, by which various therapeutic regimens could be given before the primary tumors become metastatic.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that degrade most of extra-cellular matrix (ECM) proteins. It plays an important role in the development of various diseases including cancer [3] , inflammation, neurological and cardiovascular diseases. In the case of cancer, MMPs not only have distinct roles in tumor angiogenesis, but also affect multiple signaling pathways to control the balance between growth and antigrowth signals in the tumor microenvironment. Membrane type-1 matrix metalloproteinase (MT1-MMP) has been shown to be a key member of the MMP family with much biological and pathological significance [4, 5] . Specifically, MT1-MMP is intrinsically associated with the plasma membrane of normal and tumor cells and remodels the extracellular matrix (ECM). In patients with breast cancer, MT1-MMP has been reported with high expression in both serum and local lesions [6, 7] . Although the failures of applications of MMP inhibitors in tumor prevention and therapy have been reported [8, 9] , there are accumulating reports about the potential of utilization MMP as target for cancer diagnosis [10] [11] [12] .
So far, MT1-MMP targeting peptides for breast cancer imaging and therapy are being widely studied in both experimental and clinical settings [13] [14] [15] [16] . The first reason of development of small molecules capable to track MT1-MMP in vivo is to help investigating the nature of MT1-MMP expression, distribution, and its biological and pathological functions. Secondly, a specific MT1-MMP targeting molecule would also provide the chance of earlier detection and characterization of disease and evaluation of treatment in diseases where MT1-MMP is overexpressed. Recently, we have developed a high MT1-MMP affinity peptide, named AF7p, by phage display peptide library screening technique. MT1-MMP high expressed tumor was successfully imaged in vivo by a near infrared dye labeled AF7p, suggesting the potential of utilizing AF7p for MT1-MMP targeted tumor detection [12] . Compared with optical imaging, radioisotope mediated imaging is more sensitive and accurate in clinic with less tissue penetration and quantification limitation. Currently both single photon emissions computed tomography (SPECT) and positron emission tomography (PET) are well developed [17] [18] [19] . Generally, PET imaging holds great promise in visualization of biology activities, but to some extent the short half-life of positron emitting radionuclide, high cost of instruments and the complicated preparation of tracers slow down the application of PET in clinic. On the other hand, SPECT can offer a simple and inexpensive procedure with readily available 99m Tc through inexpensive 99 Mo99m Tc generator [20] [21] [22] . Overall, SPECT is more likely to be a cost-effective technique in early detection of breast cancer in clinical practice [23] .
In the present study, to develop an SPECT probe for breast cancer early diagnosis, we modified AF7p with 6-hydrazinonicotinic acid (HYNIC) as the biomolecule for preparing a 99m Tclabeled MT1-MMP targeted imaging agent. The preparation, stability, biodistribution and tumor tagetability of [
99m Tc]-(HYNIC-AF7p)(tricine)(TPPTS) was presented and evaluated.
Our results suggested that [ 99m Tc]-(HYNIC-AF7p) is promising for MT1-MMP overexpressed tumor detection with high affinity and specificity.
Materials and Methods

Reagents
Chemicals were purchased from Sigma-Aldrich (USA) and were used without further purification. Side chain protected peptide with the sequence of His-Trp-Lys(Dde)-His-Leu-His-AsnThr-Lys(Dde)-Thr-Phe-Leu was custom-made by the GL Biochem, Ltd. (Shanghai, China). Na 
Synthesis of HYNIC-conjugated AF7P
The HYNIC-AF7p conjugate was prepared by coupling AF7p with HYNIC-NHS in slightly basic condition (pH 8.5) in DMF [24, 25] . Briefly, NHS-HYNIC (216.03 μg, 0.8641 μmol) and AF7p-Dde (1.23 mg, 0.6043 μmol) were dissolved in DMF (200 μL) and DIPEA (0.43 μL, 2.63 μmol) was further added to adjust pH around 8 to 8.5. The mixture was stirred for 10 h at room temperature. After dried under vacuum, the HYNIC-AF7p-Dde peptide was dissolved in 190 μL DMF. The Dde-group was removed by treating HYNIC-AF7p-Dde with 5% hydrazine (10 μL) for 40 min at room temperature. The product was then isolated and purified by HPLC. The fraction at retention time of 11.93 min was collected. Lyophilization of the combined collections afforded the expected product, HYNIC-AF7P. Matrix-assisted laser desorption/ionization (MALDI) time-of-light (TOF) mass spectral data of HYNIC-AF7p was m/z = 1839.61 for [M + H]+ (C87H125N25O20, calculated molecular weight 1839.95 Da). The purity of all the final products were confirmed by analytical HPLC, using 5% to 65% acetonitrile containing 0.1% TFA versus distilled water containing 0.1% TFA over 30 minutes at a flow rate of 1 mL/ min (C18 column, 5 μm, 120Å, 250 × 4.6 mm) and purity > 95%.
Synthesis of [
99m Tc]-(HYNIC-AF7p) (tricine) (TPPTS) TcO 4 (100 μL, 370 MBq) in saline were added into a 5 mL Eppendorf tube. The reaction mixture was kept at room temperature for 10 min. To the reaction mixture above was added 100 μL of the TPPTS solution (50 mg/mL in 25 mM succinate buffer, pH 5.0). The vial containing the reaction mixture was sealed, cramped, and heated at 90°C for 30 min. After cooling to room temperature, sample was analyzed by radio-HPLC. The radio-HPLC method used a HP Hewlett Packard Series 1100 HPLC system equipped with a Radioflow Detector LB509 and a reversed-phase Zorbax SB-C18 column (4.6 mm × 250 mm, 5 μm). The flow rate was 1 mL/ min. The gradient mobile phase started with 90% solvent A (0.1% TFA in water) and 10% solvent B (0.1% TFA in acetonitrile) to 30% solvent A and 70% solvent B at 24 min to 0% solvent A and 100% solvent B at 27 min, followed with 90% solvent A and 10% solvent B at 30 min. Gelman Sciences silica-gel paper strips was used in ITLC method. A 1:1 mixture of acetone and saline were used as eluent. The 
In vitro stability of [ 99m Tc]-(HYNIC-AF7p) (tricine) (TPPTS)
100 μL of [ 99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) was added to either 0.9% physiological saline or 1 mg/mL cysteine solution. The total volume was adjusted to 400 μL. The mixed solution was incubated at 37°C. After 1 h, 2 h, 3 h, 4 h, 5 h and 6 h incubation, the radiochemical purity for [
99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) at each time point was detected by radio-HPLC as described above.
Tumor immunohistochemistry
MDA-MB-435 and A549 tumor bearing mice were sacrificed and tumors were frozen in OCT embedding medium. Cryosections were cut into 4 μm and subjected to staining. Briefly, tumor slides were dried in the air and fixed with cold acetone for 20 min and dried again in the air for 30 min at room temperature. After blocking with 10% BSA for 30 min, the sections were incubated with rabbit anti-MT1-MMP antibody (10 μg/mL, Abcam, MA) for 60 min at room temperature in the dark, and then visualized with FITC-conjugated donkey anti-rabbit secondary antibody. Finally, the slices were mounted with DAPI-containing mounting medium under a fluorescence microscope (Olympus, X81). Fluorescence pictures were taken using FITC filter settings (excitation = 490 nm, emission = 520 nm).
Fluorescent staining
The MDA-MB-231 and A549 tumor cells were cultured at 37°C and 5% CO 2 in DMEM containing 10% fetal bovine serum (FBS). MDA-MB-231 and A549 cells were seeded into eight-well chamber at the concentration of 1×10 4 cells/well for cell immunostaining. The next day, cells were fixed by 90% cold ether for 20 min at -20°C. After being blocked by 10% BSA at 37°C, MDA-MB-231 and A549 cells were detected using 2 μg/mL rabbit anti-MMP14 primary antibody for 2 h at room temperature, and then visualized by FITC conjugated donkey anti-rabbit secondary antibody (1: 100 dilution) together with 10 nM of Cy5.5 (ex/em: 675/695 nm) conjugated AF7p, Cy5.5-AF7p [12] . After washing steps, cells were mounted with 4 0 , 6-diamidino-2-phenylindole (DAPI)-containing mounting medium and observed with a fluorescence microscope. For blocking experiment, fixed MDA-MB-231 and A549 cells were seeded into another eight-well chamber at the concentration of 1×10 4 cells/well and blocked with 10% BSA for 1 h. Next, 5 μM free AF7p was added into each well before Cy5.5-AF7p (10 nM) was added. After washing steps, cells were mounted with 4 0 , 6-diamidino-2-phenylindole (DAPI)-containing mounting medium and observed with a fluorescence microscope.
In vitro cytotoxicity of AF7p analogs 
Imaging study
The imaging study was performed using the female BALB/c nude mice bearing the MDA-MB-231 tumors and A549 tumors. Each tumor-bearing mouse was administered intravenously with [ Tc]-(HYNIC-AF7P)(tricine)(TPPTS) was injected. Animals were placed prone on a two-head γ-camera (SIEMENS, E. CAM) equipped with a parallel-hole, low-energy, and high-resolution collimator. Posterior images were acquired at 0.5, 2 and 4 hours post injection (p.i.). The acquisition count limits were set at 700k. After completion of imaging, animals were sacrificed by cervical dislocation.
In vivo biodistribution study
Animals were divided into 4 groups (n = 3) for 4 time points with approximately equal distribution of tumor sizes on the day before the study. At 0.5, 1, 2, and 4 h after intravenous administration of [
99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS), MDA-MB-231 tumor bearing mice were euthanized. Blood, heart, lung, liver, kidney, stomach, intestine, spleen, pancreas, brain, muscle and tumor were excised, weighed and counted for radioactivity. The organ uptake was calculated as a percentage of the injected dose per gram of wet tissue (%ID/g).
Statistical analysis
Results were expressed as mean ± SD. Two-tailed paired and unpaired Student's t tests were used to test differences within groups and between groups, respectively. P values < 0.05 were considered statistically significant. 
Results
Radiochemistry
TPPTS to form the ternary ligand complex [ 99m Tc](HYNIC-AF7P)(tricine)(TPPTS). After
Sep-Pak C 18 column purification, the radiochemical purity was found to be above 95% determinated by analytical Radio-HPLC (Fig 1) . The HPLC retention time was 9.2 min for [ 99m Tc]
(HYNIC-AF7P)(tricine)(TPPTS) and the specific activity of final product was 1200 mCi/μmol. The partition coefficient of [ 
Stability
For in vivo application, we have to make sure the probe keeps intact before it arrives at the tumor area. We then compared the in vitro stability of [ decreased slightly from 96.8 ± 1.12% at the beginning to 93.5 ± 2.27% (Fig 2A) . Similarly, the amount decreased from 96.8 ± 1.52% to 94.2 ±1.72% in the solution containing excess cysteine during the 6 hours incubation (Fig 2B) . It is quite clear that [ 99m Tc]-(HYNIC-AF7P)(tricine) (TPPTS) is able to maintain its stability over6 h in saline and in the presence of excess cysteine.
Before performing in vivo imaging, we also evaluated the overexpression of MT1-MMP in MDA-MB-231 tumors xenograft by immunohistochemistry. As expected, MT1-MMP was highly expressed in MDA-MB-231 tumor sections, verified by fluorescent immunostainingusing a MT1-MMP antibody (Fig 3) .
Cell fluorescence staining
To determine the AF7p binding specificity with MT1-MMP in vitro, AF7p was labeled with a near infrared dye, Cy5.5 (ex/em: 675/695 nm) for visualization of the binding of AF7p with MT1-MMP. Two cell lines with different amount of MT1-MMP expression (Fig 3) were chosen for cellular and live animal studies. Specifically, MDA-MB-231 cell that highly expresses of MT1-MMP and A549 cell which low expresses of MT1-MMP were used for investigations of AF7p specificity to MT1-MMP. Structure and characterizations of Cy5.5-AF7p were shown in S1 Fig and Fig 4A. As shown in Fig 4B, cell fluorescent staining was performed to verify the binding between Cy5.5-AF7p and MT1-MMP in vitro. As we expected, strong fluorescent signals from Cy5.5-AF7p was observed on MDA-MB-231 cells, while little was found in A549 cells treated with Cy5.5-AF7p. To confirm the specific binding between Cy5.5-AF7p and MT1-MMP, MT1-MMP antibody and Cy5.5-AF7p were used simultaneously for labeling of Tc]-(HYNIC-AF7P)(tricine)(TPPTS) is mediated by MT1-MMP. Taken SPECT imaging of MT1-MMP in different tumor models results, we consider AF7P is MT1-MMP dependent and specific. It should be noted that besides tumor, kidneys, and bladder also demonstrated strong signals which is consistent with ex vivo distribution data ( Table 1 ), indicating that the tracer is mainly excreted through the renal-urinary routes.
Biodistribution
The biodistribution study was performed using the BALB/c nude mice bearing MDA-MB-231 human breast cancer xenografts. The biodistribution of [ Tc]-(HYNIC-AF7P)(tricine)(TPPTS) had the best T/N ratios for blood (11.11 ± 0.74), liver (0.75 ± 0.05), and muscle (4.17 ± 0.49) ( Table 2 ).
Discussion
In this study, we used HYNIC as the BFC and tricine/TPPTS as coligands to prepare [ 99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) for in vivo SPECT imaging of breast cancer. The MT1-MMP targetability of AF7p was evaluated as a breast cancer SPECT imaging agent. Radiolabelling of (HYNIC-AF7P)(tricine)(TPPTS) was successful with radiochemical purity higher than 95%.
The solution stability data shows that [ 99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) is stable for 6 h in PBS and even in the presence of excess cysteine. Further evaluations showed that the kit formulation was stable, which is important for future clinical translation [14, 15] . In particular, breast tumor analysis showed good tumor uptake and T/N ratios. Based on its biodistribution and in vivo SPECT imaging results, [ 99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) would be useful for imaging thorax, head and neck and extremities tumors with highly expressed MT1-MMP. We also found that [ 99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) was excreted rapidly via liver and renal route with very little radioactivity accumulation in the blood and muscle at 1 h post injection. In spite of the slow clearance from bone observed in the biodistribution data (Table 1) , the images obtained at 2 h post injection showed a good tumor to background uptake ratios. This may be caused by the difference of [ 99m Tc]-(HYNIC-AF7P)(tricine)(TPPTS) injected activity between the biodistribution mice and the planar imaged mice. It is possible that increased mass of (HYNIC-AF7p) (tricine)(TPPTS) injected in the higher imaging doses could mask nonspecific binding to blood proteins and other normal tissues [15, 16] . The administration of higher doses of [ Tc coupled with selective tumor uptake and rapid clearance from non-targeting organs makes it a promising agent for breast cancer detection, which remains to be validated preclinical. Supporting Information 
